Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

Author Profile

Richard Channick, MD

Dr. Richard Channick is Director of the Pulmonary Hypertension and Thromboendarterectomy Program at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School. Dr. Channick received his medical degree at Temple University Medical School, where he was elected to the Alpha Omega Alpha Medical Honor Society. He did his residency and was chief resident at University of Massachusetts Medical Center. He did a Pulmonary and Critical Care Fellowship at University of California, San Diego Medical Center. Dr. Channick has published more than 100 original articles, chapters and reviews focused on all aspects of pulmonary hypertension. He serves on many national and international leadership committees including the American Thoracic Society Pulmonary Circulation Program Committee and the ACCP Pulmonary Vascular Disease Network Steering Committee. He is currently Chair of the Scientific Leadership Committee for the Pulmonary Hypertension Association. Dr. Channick has served on the steering committees for several pivotal clinical trials in pulmonary hypertension and lectures nationally and internationally.

Clinical Interests
  • Pulmonary hypertension
  • Thromboembolic disease
  • Critical care

Investigative Interests

  • Chronic thromboembolic pulmonary hypertension
  • Pathogenesis of primary pulmonary hypertension
  • New therapies for pulmonary hypertension, including inhaled ntiric oxide

Selected Publications
  1. Jamieson SW, Auger WR, Fedullo PF, Channick RN, Kriett JM, Tarazi RY, Moser KM. Experience and results in 150 pulmonary thromboendarterectomy operations over a 29 month period. J Thorac Cardiovasc Surg 1993;106:116-127.
  2. Channick RN, Hoch RP, Newhart JW, Johnson FW, Smith CM. Improvement in hypoxemia and pulmonary hypertension following nitric oxide inhalation in a patient with end-stage pulmonary fibrosis. Am J Respir Crit Care Med 1994;149:811-4.
  3. Channick RN, Newhart JW, Johnson FW, Moser KM. Inhaled nitric oxide reverses hypoxic pulmonary vasoconstriction in dogs: a practical nitric oxide delivery and monitoring system. Chest 1994;105:1842-7.
  4. Channick RN. Primary pulmonary hypertension. In: Atlas of Heart Diseases. Ed. Braunwald E, Current Medicine 1995; Volume 3, pp 4.1-4.20.
  5. Channick RN. Pulmonary hypertension. In: Manual of Clinical Problems in Pulmonary Medicine. Bordow RA, Moser KM, eds. Fourth edition. Little Brown and Company, 1995 pp 477-85.
  6. Kerr KM, Auger WR, Fedullo PF, Channick RN, Yi ES. Moser KM. Large vessel pulmonary arteritis mimicking chronic thromboembolic disease. Am J Respir Crit Care Med 1995;152:367-73.
  7. Bradley SP, Auger WR, Moser KM, Fedullo PF, Channick RN, Bloor CM. Right ventricular pathology in chronic pulmonary hypertension. Am J Cardiol 1996;78:584-7.
  8. Channick RN, Newhart JN, Johnson FW, Williams PJ, Auger WR, Fedullo PF, Moser KM. Pulsed delivery of inhaled nitric oxide in patients with pulmonary hypertension: An ambulatory delivery system in initial clinical tests. Chest 1996;109:1545-9.
  9. Hirsh AM, Moser KM, Auger WR, Channick RN, Fedullo PF. Unilateral thromboembolic pulmonary artery occlusion: Does it cause post-obstructive vasculopathy? Am J Respir Crit Care Med 1996;153:A90.
  10. Morris TA, Auger WR, Ysrael MZ, Olson LK, Channick RN, Fedullo PF, Moser KM. Parenchymal scarring is associated with restrictive spirometric defects in patients with chronic thromboembolic pulmonary hypertension. Chest 1996;110:399-403.
  11. Wilson WC, Kapelanski DP, Benumof JL, Newhart JW, Johnson FW, Channick RN. Inhaled nitric oxide (40 ppm) during one-lung ventilation, in the lateral decubitus position, does not decrease pulmonary vascular resistance or improve oxygenation in normal patients. J Cardiothorac Vasc Anesth 1997;11:172-6.


Dr. Richard Channick


  • Fluid and Sodium Management
  • WHO Group 4 PH (CTEPH Treatment): Surgical vs. Medical For more than two decades, WHO Group 4 PH (CTEPH, chronic thromboembolic pulmonary hypertension) has been treated surgically through pulmonary thromboendarterectomy (PTE). In late 2013, riociguat was approved by the U.S. Food & Drug Administration (FDA) for the treatment of inoperable or PH occurring post-PTE. Following this approval, expert consensus guidelines on the diagnosis and treatment of PH have incorporated medical management of these specific PH patients into the treatment algorithm. However, PTE remains the recommended intervention in patients deemed operable as it can hemodynamically stabilize correctly selected patients. These guidelines, however, remain vague about the definition of operability as it relies on the technical abilities of the surgical and medical multidisciplinary teams and a paucity of long-term, multi-center outcomes data. This session seeks to a) describe the role of CT angiography in assessing surgical accessibility in CTEPH patients; b) discern operable versus inoperable CTEPH; interpret the surgical classification system for CTEPH; d) explain the benefits of PTE; and e) discuss the therapeutic options for those patients with inoperable or recurrent CTEPH, including PH-targeted medical therapy and/or balloon pulmonary angioplasty.

Journal Articles

  • Chronic Thromboembolic Pulmonary Hypertension: Current Care This issue of Advances in Pulmonary Hypertension is dedicated to the topic of chronic thromboembolic pulmonary hypertension (CTEPH). It is imperative that all healthcare providers who care for patients with pulmonary hypertension be aware of the appropriate screening tests and treatment of this disease as CTEPH is potentially curable with surgery. Articles in this issue review the diagnostic evaluation, the surgical procedure of pulmonary thromboendarterectomy (PTE) (also referred to as pulmonary endarterectomy [PEA]), post-operative complications, care of surgical patients after hospital discharge, as well as the role of medical therapy of CTEPH.
  • Editor's Memo Out with a Bang
  • Editor's Memo As a participant in the 4th World Symposium on Pulmonary Hypertension, held February 2008 in Dana Point, California, I was struck by several things-first was the beautiful setting.
  • Editor's Memo It is with great excitement that I introduce the Fall 2009 issue of Advances, devoted to pulmonary hypertension in the setting of lung or respiratory disease (or WHO Diagnostic Group III). Dr Omar Minai has done an outstanding job of coordinating the issue and contri-buting one of the articles.
  • Editor's Memo The invaluable role of non-physician members of the PAH care team has been impressed on me in recent months.
  • Editor's Memo I clearly remember the first PAH patient I cared for who underwent lung transplantation. She was a fairly typical IPAH patient—mid 40s and previously healthy—who had been literally struck down by this disease.
  • Editor's Memo: This past June I winged my way to my former home state, California, for PHA's 9th International Conference and Scientific Sessions. As I rode in from the airport, past the uniquely Southern Californian strip malls and bungalows, I reflected on how much has changed in this meeting, and this disease.
  • Editor's Memo: Exercising Our Resources About PH The topic of exercise as it relates to pulmonary vascular disease is a critical one. As we all know, most of the symptoms of pulmonary hypertension occur not at rest, but during exertion.
  • Endothelin Receptor Antagonism: A New Era in the Treatment of Pulmonary Arterial Hypertension The endothelin system has been extensively studied over the last several years. It is clear that endothelin-1 (ET-1) is a key mediator in pulmonary vascular biology and physiology.
  • Medical Therapy for Chronic Thromboembolic Pulmonary Hypertension Chronic thromboembolic pulmonary hypertension (CTEPH) is pulmonary hypertension (PH) secondary to chronic emboli, obstructing the pulmonary arteries. This results in increased pulmonary vascular resistance and right ventricular failure. CTEPH is the only form of PH that is potentially curable, through a surgical procedure that removes the chronic emboli: pulmonary thromboendarterectomy (PTE). The first step in managing patients diagnosed with CTEPH is to determine if they are operable. The use of medical therapy should never delay referral for surgery, which should be done at a specialized center with expertise in CTEPH. Since a significant proportion of CTEPH patients are not surgical candidates, or are among the 10% to 15% of patients that have persistent or recurrent PH after surgery, there is a need for effective medical therapy. The use of several pulmonary arterial hypertension (PAH)-targeted agents have been studied, mostly in small uncontrolled trials. A recent Phase 3 clinical trial found riociguat, a stimulator of soluble guanylate cyclase (sGC), to be effective for inoperable CTEPH.
  • PH Grand Rounds: Pulmonary Artery Filling Defects: Are They All the Same? Section editor's note: The diagnostic evaluation of pulmonary hypertension (PH) is an extensive, yet specific, process. Each individual study is significant, but it is truly the insightful analysis of the combination of studies that assists us most in making the correct diagnosis. In this issue's PH Grand Rounds, we congratulate Dr. Al-Naamani and her colleagues for reminding us to consider a more in-depth examination of the data prior to making what seems to be an obvious diagnosis. This case not only imparts valuable information on this particular diagnosis, it also demonstrates how this type of thought process is vital to both the diagnosis and therapy for our patients.
  • Pulmonary Arterial Hypertension: Therapeutic Considerations Editor-in-Chief Victor Tapson, MD, interviewed a select panel of experts in pulmonary hypertension to obtain their review and comments on the new evidence-based clinical practice guidelines of the American College of Chest Physicians.
  • Pulmonary Hypertension Roundtable Pulmonary Hypertension in Lung/Respiratory Disease: How Important? What to Do?
  • Pulmonary Hypertension Roundtable Integrating Current Strategies for Continuing Assessment of Pulmonary Arterial Hypertension
  • Pulmonary Hypertension Roundtable Pulmonary Hypertension Roundtable: Recapping 5 Years, Exploring Emerging Approaches
  • Pulmonary Hypertension Roundtable Meeting the Challenge of Surgery and Pulmonary Hypertension: How to Manage the “Hemodynamic Environment” to Optimize Outcomes
  • Pulmonary Hypertension Roundtable Recapping Highlights from Pulmonary Hypertension Association Scientific Sessions and Identifying Key Issues Driving Translational Research
  • Pulmonary Hypertension Roundtable: CTEPH Experiences and Expertise On February 6, 2014, a group of physicians with expertise related to Chronic Thromboembolic Pulmonary Hypertension (CTEPH) met on a conference call to discuss topics related to the disease. The call was hosted by the guest editor of this issue, Richard Channick, MD, the Director of the Pulmonary Hypertension and Thromboendarterectomy Program at Massachusetts General Hospital. Dr. Channick was joined by Victor Tapson, MD, Professor of Medicine in the Division of Pulmonary and Critical Care Medicine at Duke University Medical Center and Director of the Duke Pulmonary Vascular Disease Center; Joanna Pepke-Zaba, PhD, FRCP, Lead Physician and Director, National Pulmonary Vascular Diseases Unit at the Papworth Hospital, University of Cambridge, UK; Vallerie McLaughlin, MD, Professor of Internal Medicine at the University of Michigan; and Bill Auger, MD, Professor of Clinical Medicine and Director of Academic Affairs of the PTE Program at University of California-San Diego.
  • Roundtable: Other Rare Disorders Associated with Pulmonary Hypertension While pulmonary hypertension itself is a rare disorder, its association has been identified in conjunction with other rare disorders,which is the theme of this issue of Advances in Pulmonary Hypertension. Co-guest editor Sonja Bartolome, MD, facilitated a discussion regarding the experiences and perceptions of leading PH experts—many authors in this issue—on this topic. Participating were co-guest editor Kelly Chin, MD, University of Texas Southwestern Medical Center; Murali Chakinala, MD, Washington University School of Medicine; Richard Channick, MD, Harvard Medical School; Jean Elwing, MD, University of Cincinnati Medical Center; and adding to the comments later, Robert Baughman, MD, University of Cincinnati. Their conversation follows.
  • What’s on the Horizon in Therapy, From Current Approaches to Experimental Agents The past several years have seen dramatic changes in the therapeutic options and outlook for patients with pulmonary arterial hypertension (PAH).